L'intérêt à découvert pour Gritstone Bio donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Gritstone Bio. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Gritstone Bio (NASDAQ:GRTS) Stock, Rapport sur les intérêts à découvert

Gritstone Bio

Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.

Gritstone Bio Inc

As California's cannabis market expanded after legalization, several leading companies seemed poised for dominance. However, due to mismanagement, regulatory pressures and market saturation, many of these giants have collapsed. Here's a closer look at the industry's most notable failures.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">MedMen: From Unicorn To Bankruptcy</h3>
MedMen, once celebrated as the &#8220;Apple Store of Weed,&#8221; reached a $2 billion valuation. However, rapid expansion, failed acquisitions, and leadership turnover created financial turmoil. By April 2024, MedMen had filed for bankruptcy with $411 million in liabilities.
<h3 class="wp-block-heading">Eaze: The Uber Of Weed Falls</h3>
Eaze, once California's largest cannabis delivery service, <a href="https://www.benzinga.com/markets/cannabis/24/04/38282181/eaze-delivery-workers-threaten-first-cannabis-strike-of-2024-amid-ongoing-negotiations">defaulted </a>on a $36.9 million loan and was later acquired by billionaire James Henry Clark. Despite the change in ownership, Eaze could not recover from high operating costs, regulatory burdens and competition from unlicensed operators. 
The company will shut down by December 2024, leaving 500 employees without jobs. This failure underscores the harsh market conditions many cannabis businesses face.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41053140/i-dealt-with-gangsters-shakedowns-loan-sharks-and-government-corruption-says-entrepreneur-who-bu"> &#8216;I Dealt With Gangsters, Shakedowns, Loan Sharks And Government Corruption,&#8217; Says Entrepreneur Who Built The First Cannabis Unicorn</a>
<h3 class="wp-block-heading">FlowKana: Bye Bye To The Sustainable Dream</h3>
FlowKana was a pioneer in promoting sustainability and small farmers, but it struggled with <a href="https://www.benzinga.com/topic/california-cannabis">California&#8217;s regulatory environment </a>and a market flooded with excess supply. Despite raising $175 million and becoming California's top-selling flower brand in 2018, the company couldn't survive the dramatic drop in wholesale cannabis prices.&nbsp;
FlowKana paid as low as $350 per pound for lower-grade flowers in 2019, far below sustainable levels. The company ceased operations in 2023, reflecting the challenges of balancing sustainability with profitability in a turbulent market.
<h3 class="wp-block-heading">Herbl: The Supply Chain Giant Stumbles</h3>
Herbl, once a major force in <a href="https://www.benzinga.com/topic/california-cannabis">California's cannabis distribution network</a>, handled approximately $700 million in annual sales and worked with over 1,000 licensed retailers. However, the company's collapse in 2024 was marked by severe liquidity problems and an inability to keep up with mounting unpaid invoices.&nbsp;
Facing a canceled line of credit from its primary lender, East West Bank, Herbl&#8217;s financial health rapidly <a href="https://mjbizdaily.com/big-california-marijuana-distributor-herbl-collapses-brands-left-unpaid/">deteriorated</a>, leading to millions of dollars owed to cannabis brands and the state in unpaid taxes.&nbsp;
The company laid off the majority of its workforce, leaving only a small team to manage collections from retailers, many of whom were also struggling to pay what they owed. Herbl's receivership underscores the fragility of <a href="https://www.benzinga.com/topic/california-cannabis">California's cannabis infrastructure</a>, where even the largest and seemingly best-established players cannot escape the pressures of overregulation, high taxes and an unpredictable market
Read Also:<a href="https://www.benzinga.com/markets/cannabis/21/11/24264808/co-founder-of-flow-cannabis-calls-for-tax-revolt-in-california-says-regulatory-system-unworkable"> Co-Founder of Flow Cannabis Calls For Tax Revolt In California, Says Regulatory System &#8216;Unworkable&#8217;</a>
<h3 class="wp-block-heading">A Wake-Up Call</h3>
These high-profile failures reveal the volatility of <a href="https://www.benzinga.com/topic/california-cannabis">California's cannabis market</a>. Overregulation, high taxes and competition from illicit operators have strained even the biggest companies. The collapse of MedMen, Eaze, FlowKana and Herbl has left thousands of people jobless, and the cannabis sector grapples with the need for reform to prevent further losses.
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41236050/californias-largest-cannabis-delivery-service-closes-down-lays-off-500-workers"> California&#8217;s Largest Cannabis Delivery Service Closes Down, Lays Off 500 Workers</a>

Cannabis

News

Entrepreneurship

Financing

Asset Sales

Management

Markets

Epic Cannabis Fails You Should Know About: MedMen, Eaze And Others Go Down In California Meltdowns

Toronto-Dominion Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) agreed to pay approximately $3.09 billion in fines to U.S. authorities after pleading guilty on Thursday to money laundering-related charges in an <a href="https://www.benzinga.com/government/24/10/41271816/td-bank-to-face-3b-penalty-growth-limits-in-us-settlement-over-anti-money-laundering-failures">ongoing case</a> brought by federal prosecutors, who accused the Canadian bank of essentially making it easy for criminals and cartels to move money around the world for nearly a decade.
"By making its services convenient for criminals, TD Bank became one," said Attorney General Merrick B. Garland on Thursday. "Today, TD Bank also became the largest bank in U.S. history to plead guilty to Bank Secrecy Act program failures, and the first U.S. bank in history to plead guilty to conspiracy to commit money laundering."  
The penalties are the largest ever imposed by U.S. authorities on a bank for money laundering violations.
Read Also: <a href="https://www.benzinga.com/government/24/10/41271816/td-bank-to-face-3b-penalty-growth-limits-in-us-settlement-over-anti-money-laundering-failures">TD Bank To Face $3B Penalty, Growth Limits In US Settlement Over Anti-Money Laundering Failures</a>
Referring to court documents from between January 2014 and October 2023, the Justice Department's Office of Public Affairs <a href="https://www.justice.gov/opa/pr/td-bank-pleads-guilty-bank-secrecy-act-and-money-laundering-conspiracy-violations-18b">stated, </a>"TD Bank had long-term, pervasive, and systemic deficiencies in its U.S. AML policies, procedures and controls but failed to take appropriate remedial action."
<h1 class="wp-block-heading">Employees Involved?</h1>
Federal prosecutors also said some of the bank's employees had enabled the money laundering the bank was slow to detect and address.
"TD Bank's persistent prioritization of growth over controls allowed its employees to break the law and facilitate the laundering of hundreds of millions of dollars," stated Michael J. Hsu, the acting Comptroller of the Currency, <a href="https://www.nytimes.com/2024/10/10/business/td-bank-fine.html">reported</a> the New York Times.
<h1 class="wp-block-heading">Rare But Stern Response: Asset Cap</h1>
The Office of the Comptroller imposed an asset cap that will prevent TD Bank from growing beyond its current $370 billion in assets and curbing its growth in a key market. This marks the first such restriction on a major bank since Wells Fargo in 2018. &nbsp;
"The imposition of an asset cap will ensure that the bank focuses on building proper controls commensurate with its risk profile," Hsu said.
The TD Bank Group, Canada's second-largest bank, has over 1,000 branches in the U.S.&nbsp;
"The bank is also pleading guilty to criminal charges brought by law enforcement authorities," <a href="https://www.federalreserve.gov/newsevents/pressreleases/enforcement20241010a.htm">noted</a> the Federal Reserve in a press release. "The Board&#8217;s action will help ensure that TD operates in compliance with all U.S. laws and regulations."
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41250936/this-wells-fargo-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Chewy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday</a></li>
</ul>
TD Price action: TD Bank stock closed Thursday 5.29% lower at $59.44 per share at market close on Thursday.
Photo: JHVE Photo via Shutterstock

Government

Large Cap

Legal

Global

General

TD Bank Pays $3B Fine After Pleading Guilty In Money Laundering Case, 'Making Its Services Convenient For Criminals'

A Major League Baseball team is up for sale and while billionaire Warren Buffett likely isn't buying the team, he could benefit thanks to a small stake<a href="https://www.benzinga.com/general/sports/23/11/35837148/warren-buffett-finds-sweet-spot-hits-home-run-with-stake-in-major-league-baseball-team"> in another team.</a>
What Happened: The sale of <a href="https://www.benzinga.com/topic/mlb">Major League Baseball </a>(MLB) teams has been rare in recent years, which means a new sale could reset the valuation metrics of teams, an item that shareholders of Atlanta Braves Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRA#NASDAQ">BATRA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRK#NASDAQ">BATRK</a>) will be watching.
The Pohlad Family, which has owned the Minnesota Twins since 1984, announced Thursday that the team is up for sale.
Carl Pohlad, who passed away in 2009, bought the Twins for $44 million in 1984, as reported by <a href="https://www.sportico.com/business/team-sales/2024/minnesota-twins-for-sale-pohlad-family-1234800592/">Sportico</a>. His children Jim, Bob and Bill inherited the team upon his death. Jim Pohlad currently serves as the team's controlling owner.
"After months of thoughtful consideration, our family reached a decision this summer to explore selling the Twins. As we enter the next phase of this process, the time is right to make this decision public," the team said.
The Twins won World Series titles in 1987 and 1991 as the Twins and the franchise previously won a title as the Washington Senators in 1924, prior to moving to Minnesota in 1961.
The team has made the MLB Playoffs in four of the past 10 years, winning only one playoff series over the same time period.
The Twins narrowly missed making the playoffs in 2024 with an 82-80 record. General Manager Thad Levine announced he was leaving after eight years with the team. Manager Rocco Baldelli is slated to return for a seventh season in 2025. One plus for the Twins is having managerial stability with only four managers over the last 38 years.
A negative for the team and a potential new owner will be trying to improve television revenue. A deal with Bally Sports North expired after the 2023 season and Diamond Sports Group paid a reduced rate to have Twins games in 2024. The league announced they will take over production and distribution of Twins games and negotiate future deals.
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Ownership of baseball teams like many professional sports teams is often reserved for the wealthiest people.
Baseball has a history of corporations owning teams, a rule that it no longer allows other than the Toronto Blue Jays, owned by Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>), who are grandfathered in.
Previously, other MLB teams had corporate owners, which included:
<ul>
<li>St. Louis Cardinals: Anheuser-Busch</li>
<li>Chicago Cubs: Tribune Company</li>
<li>New York Yankees: CBS</li>
<li>Seattle Mariners: Nintendo</li>
<li>Los Angeles Angels: Disney</li>
</ul>
Private equity companies can own minority stakes in MLB teams but can't own a team outright. MLB has allowed private equity investments for years, while the NFL is just now<a href="https://www.benzinga.com/general/sports/24/08/40607642/jeff-bezos-could-have-competition-if-he-wants-the-nfls-seattle-seahawks-private-equity-investments"> coming around to the practice</a> to help improve investment opportunities for team owners.
The Twins are valued at $1.7 billion by <a href="https://www.sportico.com/feature/mlb-team-values-rankings-list-1234715821/">Sportico</a>, ranking 19th of 30 MLB teams. Here are the most recent MLB team sales:
<ul>
<li>2024: Baltimore Orioles, $1.725 billion</li>
<li>2020: New York Mets, $2.42 billion</li>
<li>2019: Kansas City Royals, $1 billion</li>
<li>2017: Miami Marlins, $1.2 billion</li>
<li>2016: Seattle Mariners, $1.4 billion</li>
<li>2012: Los Angeles Dodgers, $2.15 billion</li>
</ul>
The Washington Nationals and Los Angeles Angels hired bankers for potential sales but did not end up selling the teams.
The low number of recent sales could put the Twins in demand with sports ownership often viewed as a strong investment opportunity.
This could be great news for the Atlanta Braves, which are valued at $3.4 billion, ranking sixth by Sportico.
The Braves holding company, which is publicly traded, has a market capitalization of $2.5 billion and enterprise value of $3.1 billion. While the team already trades under the Sportico valuation, the sale of the Twins at a premium to the valuation, it could see other MLB teams rise in the rankings.
Buffett owns a small stake (233,645 shares) in the publicly traded Braves via Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) and has a love for the game of baseball. The billionaire previously owned a stake in a minor league baseball team and had interest in buying the Chicago Cubs.
BATRA Price Action: Atlanta Braves Holdings stock closed Thursday at $41.57 versus a 52-week trading range of $36.78 to $46.65. The stock is down 1.1% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/04/38022637/atlanta-braves-stock-could-be-undervalued-based-on-mlb-team-valuations-did-warren-buffett-">Atlanta Braves Stock Could Be Undervalued Based On MLB Team Valuations, Did Warren Buffett Spot Another Value Stock?</a></li>
</ul>
Photos: Shutterstock

Sports

Trading Ideas

BATRA

BATRK

Warren Buffett Home Run? Billionaire's Baseball Bet Could Rise In Value With Minnesota Twins Sale

Sacramento is exploring the possibility of allowing on-site cannabis consumption at dispensaries through a new pilot program. 
If approved, this <a href="https://sacramento.granicus.com/MetaViewer.php?view_id=25&amp;clip_id=6047&amp;meta_id=795533">pilot program</a> would introduce consumption lounges, giving residents a safe and social space to enjoy cannabis legally in the capital city of California.
<h3 class="wp-block-heading">Consumption Lounge</h3>
The proposal, led by Councilmember Katie Valenzuela, would allow two types of cannabis lounges. 
The first would focus on the sale and consumption of cannabis-infused edibles and drinks, providing a more discreet option for those looking to avoid smoking.
The second would permit smoking on site with strict safety measures in place. Valenzuela has championed this initiative for two years, contending it would create a controlled environment for cannabis users to learn and engage with the product safely. "If you have kids at home, you can keep it completely away from them. It never comes into the house," she said in an <a href="https://www.abc10.com/article/news/local/sacramento-cannabis-lounges/103-cab4aee7-b84f-412b-a5c7-869e3b6c693d">interview</a> with ABC10.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Positive Signs From Previous Trials</h3>
Sacramento has already tested the concept of on-site consumption at the <a href="https://www.benzinga.com/markets/cannabis/24/07/39782466/californias-first-cannabis-friendly-state-fair-with-on-site-sales-and-consumption">State Fair </a>earlier this year.
The event allowed cannabis users to consume in a designated area, providing a glimpse of what future consumption lounges could look like.
Valenzuela says these lounges could position Sacramento as a leader in cannabis culture in the region.
"There were dozens and dozens of people there from all walks of life mingling and hanging&#8230;I could just get a picture of what this experience looked like," she said.
Maisha Bahati, CEO of Crystal Nugs, is among those preparing for the potential legalization of on-site consumption. Her dispensary already has a dedicated space for social events, from live music to game nights, once the lounges are approved. "You're going to be around like-minded people…just a normal place where people can come and can consume cannabis," she <a href="https://www.abc10.com/article/news/local/sacramento-cannabis-lounges/103-cab4aee7-b84f-412b-a5c7-869e3b6c693d">told</a> ABC10.
Two more hearings will take place before the proposal moves forward. A final vote is expected by the end of October.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a>
<h3 class="wp-block-heading">Shifting Califonia Cannabis Landscape</h3>
California's recent&nbsp;initiatives regarding cannabis include <a href="https://www.benzinga.com/markets/cannabis/24/08/40666298/will-california-embrace-cannabis-farmers-markets-and-pot-cafes-gov-newsoms-crucial-decision-ahea">farmer&#8217;s markets</a> and <a>Amsterdam-style&nbsp;cannabis&nbsp;cafes</a>. These proposals aim to alleviate the challenges facing the state&#8217;s cannabis industry.
High taxes, low prices and competition from unlicensed markets have pressured legal businesses into a downturn. In response, lawmakers are exploring solutions to stabilize the sector. Allowing small growers to sell directly and creating social consumption spaces are two possible steps.
Meanwhile, some companies have been <a href="https://www.benzinga.com/markets/cannabis/24/08/40465710/why-are-so-many-california-cannabis-companies-switching-to-hemp-products">shifting to hemp</a> to avoid heavy regulatory burdens. However, Governor Gavin Newsom recently <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">ruled out </a>most hemp products and manufacturing in the state after imposing an emergency ban for which he is facing <a href="https://www.benzinga.com/markets/cannabis/24/09/40756333/gov-newsom-proposes-emergency-rules-to-severely-restrict-hemp-products-this-will-destroy-our-bus">legal resistance</a> from industry stakeholders.
<ul>
<li>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40819034/gov-newsom-is-mulling-over-whether-to-approve-amsterdam-style-cannabis-cafes-in-california">Gov. Newsom Is Mulling Over Whether To Approve Amsterdam-Style Cannabis Cafes In California</a></li>
</ul>

Regulations

Politics

Unwinding Among Friends In A Cannabis Lounge Could Soon Be Reality In Sacramento

AMLI

American Lithium Says Taken Proactive Steps, Including Cost-cutting Measures,  To Adapt To Evolving Market Conditions

PROC

Procaps Group Says Independent Investigation Has Identified Certain Historical Transactions, To Restate Financial Statements, Plans Long-term Restructuring Plan

Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) has outperformed the market over the past 5 years by 46.06% on an annualized basis producing an average annual return of 60.09%. Currently, Vertiv Hldgs has a market capitalization of $40.30 billion. 
Buying $100 In VRT: If an investor had bought $100 of VRT stock 5 years ago, it would be worth $1,050.54 today based on a price of $107.43 for VRT at the time of writing.
<h3>Vertiv Hldgs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728595824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $1,100 Today

L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) has outperformed the market over the past 15 years by 1.04% on an annualized basis producing an average annual return of 12.78%. Currently, L3Harris Technologies has a market capitalization of $45.98 billion. 
Buying $1000 In LHX: If an investor had bought $1000 of LHX stock 15 years ago, it would be worth $6,511.28 today based on a price of $242.35 for LHX at the time of writing.
<h3>L3Harris Technologies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728595820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $6,500 Today

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares traded lower Thursday as the company hosted its <a href="https://www.benzinga.com/pressreleases/24/10/g41278525/amd-unveils-leadership-ai-solutions-at-advancing-ai-2024">"Advancing AI 2024" event.&nbsp;</a>
The Details: AMD launched several new high-performance computing solutions at the event, including fifth Gen AMD EPYC server CPUs, AMD Instinct MI325X accelerators, AMD Pensando Salina DPUs, AMD Pensando Pollara 400 NICs and AMD Ryzen AI PRO 300 series processors for enterprise AI PCs.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/10/41277250/whats-going-on-with-first-solar-stock">What&#8217;s Going On With First Solar Stock?</a>
&#8220;The data center and AI represent significant growth opportunities for AMD, and we are building strong momentum for our EPYC and AMD Instinct processors across a growing set of customers,&#8221; said AMD Chair and CEO Dr. Lisa Su.&nbsp;
&#8220;With our new EPYC CPUs, AMD Instinct GPUs and Pensando DPUs we are delivering leadership compute to power our customers&#8217; most important and demanding workloads. Looking ahead, we see the data center AI accelerator market growing to $500 billion by 2028," added Su.&nbsp;
Several partners, including Dell, Google Cloud, HPE, Meta, Microsoft and Super Micro, showcased how they deploy AMD's AI solutions at scale. Microsoft CEO Satya Nadella pointed to the company's long-standing collaboration with AMD across its product offerings and Google highlighted how AMD EPYC processors power a wide range of instances for AI, high performance and general purpose and confidential computing. 
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, AMD shares moved on heavy volume during Thursday's event and are trading above the stock's 50-day moving average of $149.92.&nbsp;
<h1 class="wp-block-heading">Will AMD Stock Go Up?</h1>
When trying to assess whether or not Advanced Micro Devices will trade higher from current levels, it's a good idea to take a look at analyst forecasts. 
Wall Street analysts have an average 12-month price target of $191.19 on Advanced Micro Devices. The Street high target is currently at $250 and the Street low target is $156. Of all the analysts covering Advanced Micro Devices, 14 have positive ratings, two have neutral ratings and no one has a negative rating.
In the last month, three analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Advanced Micro Devices have performed in recent history.
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Advanced Micro Devices is 18.47% up year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about Advanced Micro Devices, visit <a href="https://www.benzinga.com/quote/AMD">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
AMD Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, AMD shares ended Thursday's session 4% lower at $164.18.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41261919/what-happened-with-celsius-holdings-stock-today">What Happened With Celsius Holdings Stock Today?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Movers

Tech

What Happened With AMD Stock Today?

RIV Capital Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#CSE">RIV</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) and Cansortium Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TIUM#CSE">TIUM</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTCQB">CNTMF</a>) have secured approval from the New York Cannabis Control Board for their upcoming merger, marking a major consolidation in the state's fast-growing cannabis industry. 
The merger, expected to close by the end of 2024, positions the combined company to take full advantage of<a href="https://www.benzinga.com/markets/cannabis/24/05/39094250/this-cannabis-merger-will-cover-25-of-u-s-population-cansortium-riv-capital-powered-by-scottsmir"> covering 25% of the U.S. population</a> with eight cultivation and processing facilities and 42 retail dispensaries.
&#8220;We are thrilled to have received regulatory approval in New York to move forward with our business combination transaction, bringing us closer to completing this important step for both of our companies in the fourth quarter of 2024,&#8221; said Robert Beasley, CEO of Cansortium, in a press release Thursday afternoon.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">New York's Cannabis Boom</h3>
With adult-use cannabis sales now in full swing, New York has quickly become a battleground for companies looking to expand their market share. RIV Capital, which operates three retail locations in the state, has seen rapid growth in both its consumer-facing and wholesale businesses since adult-use sales began earlier this year.
Cansortium, a vertically integrated company operating under the FLUENT&#x2122; brand, brings significant expertise from other key markets, including<a href="https://www.benzinga.com/topic/florida-cannabis"> Florida</a>, Pennsylvania, and<a href="https://www.benzinga.com/topic/texas-cannabis"> Texas</a>. 
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/10/41277104/exclusive-80-growth-despite-the-chaos-how-dutchie-c3-defy-2024s-cannabis-slump"> EXCLUSIVE: 80% Growth Despite The Chaos: How Dutchie, C3 Defy 2024&#8217;s Cannabis Slump</a>
<h3 class="wp-block-heading">What This Means For Investors</h3>
For cannabis investors, this <a href="https://www.newswire.ca/news-releases/riv-capital-and-cansortium-receive-new-york-state-cannabis-control-board-approval-for-change-of-control-851372999.html">merger</a> signals a unique opportunity to gain exposure to a rapidly expanding market. RIV Capital's partnership with The Hawthorne Collective, a subsidiary of ScottsMiracle-Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>), further strengthens its position in the cannabis supply chain. Meanwhile, Cansortium's operational expertise in cultivation, production and retail will likely drive significant value for shareholders.
<h3 class="wp-block-heading">Closing Timeline And Further Details</h3>
<ul>
<li>The merger between RIV Capital and Cansortium is expected to close by the fourth quarter of 2024, pending final closing conditions. </li>
<li>Upon completion, Cansortium&#8217;s shares will continue trading on the Canadian Securities Exchange under the symbol &#8216;TIUM.U&#8217; and on the OTCQB Venture Market under &#8216;CNTMF.&#8217; </li>
<li>Further details, including the principal closing conditions, can be found in RIV Capital&#8217;s management information circular dated July 12, 2024.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41273594/tilray-reports-200m-q1-net-revenue-up-13-yoy-as-net-loss-improves"> Tilray Reports $200M Q1 Net Revenue, Up 13% YoY As Net Loss Improves</a>

Contracts

CNPOF

CNTMF

CSE:RIV

CSE:TIUM

Major Cannabis Merger Approved In New York: Can Weed Stock Investors Take Advantage?

The dividend will be paid on Nov. 15, 2024 to shareholders of record on Oct. 31, 2024. The Company&#39;s indicated annual dividend rate is&nbsp;$1.96&nbsp;per share.

Dividends

Northwest Natural Holding Increases Quarterly Dividend From $0.4875 To $0.49 Per Share

Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares fell Thursday after the company announced it entered into an agreement with certain institutional investors to purchase approximately 26.6 million shares of common stock in a <a href="https://www.benzinga.com/pressreleases/24/10/g41279369/jet-ai-announces-pricing-of-2-4-million-registered-direct-offering">registered direct offering. </a>
The Details: Jet.AI announced the pricing of the offering will be nine cents per share with gross proceeds of approximately $2.4 million to the company before deducting the estimated offering expenses. The offering is expected to close on or about Oct. 11. 
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41234302/whats-going-on-with-sofi-stock">What&#8217;s Going On With SoFi Stock?</a>
Jet.AI shares reached an intraday high of 25 cents before reversing in afternoon trading when the direct offering was announced. The stock moved lower on heavy trading volume with more than 805 million shares traded in Thursday's session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. 
<h1 class="wp-block-heading">How To Buy JTAI Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Jet AI's case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
JTAI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Jet.AI shares are up 8.57% after-hours at 8 cents after falling 11.77% in regular trading Thursday.  
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41261919/what-happened-with-celsius-holdings-stock-today">What Happened With Celsius Holdings Stock Today?</a></li>
</ul>
Image: Shutterstock

Penny Stocks

Offerings

After-Hours Center

JTAI

What Happened With Jet.AI Stock Today?

The&nbsp;dividend is payable on&nbsp;November 27, 2024&nbsp;to shareholders of record at the close of business on&nbsp;November 13, 2024.

MSC Industrial Supply Boosts Quarterly Cash Dividend From $0.83 To $0.85 Per Share

6 analysts have shared their evaluations of Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $214.17, along with a high estimate of $233.00 and a low estimate of $194.00. Surpassing the previous average price target of $206.83, the current average has increased by 3.55%.
<img src="https://www.benzinga.com/files/images/story/2024/1728594098_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Assurant among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grace Carter</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$233.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$217.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>John Nadel</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Tommy McJoynt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$194.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>John Nadel</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Assurant. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Assurant compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Assurant's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Assurant's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AIZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Assurant analyst ratings.</a>
<h2>All You Need to Know About Assurant</h2>
Assurant Inc offers a range of property-casualty, health, employee benefit, and warranty insurance to a client base made up of individuals and institutions. Its segments are Global Housing, Global lifestyle, Corporate and Other. Global Housing provides lender-placed homeowners insurance, lender-placed manufactured housing insurance and lender-placed flood insurance; renters insurance and related products; and voluntary manufactured housing insurance, voluntary homeowners insurance and other specialty products. Global Lifestyle, the key revenue-generating segment, provides mobile device solutions and extended service products and related services for mobile devices, consumer electronics and appliances; vehicle protection; and credit protection and other insurance products.
<h3>Assurant: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Assurant's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 7.08%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Assurant's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 6.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Assurant's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.8%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Assurant's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.56%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.42, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

6 Analysts Have This To Say About Assurant

Across the recent three months, 4 analysts have shared their insights on Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $84.5, a high estimate of $90.00, and a low estimate of $68.00. Observing a 6.96% increase, the current average has risen from the previous average price target of $79.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594088_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Climb Global Solutions is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Climb Global Solutions. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Climb Global Solutions compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Climb Global Solutions's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Climb Global Solutions's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLMB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Climb Global Solutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Climb Global Solutions: A Closer Look</h2>
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The Company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
<h3>A Deep Dive into Climb Global Solutions's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Climb Global Solutions's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.66% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Climb Global Solutions's net margin is impressive, surpassing industry averages. With a net margin of 3.63%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Climb Global Solutions's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.28%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.11%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Climb Global Solutions adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLMB

Breaking Down Climb Global Solutions: 4 Analysts Share Their Views

Ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $262.63, accompanied by a high estimate of $302.00 and a low estimate of $190.00. A decline of 3.85% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594071_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Biogen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$302.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$244.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$288.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$316.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Biogen's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Biogen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>About Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>A Deep Dive into Biogen's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Biogen showcased positive performance, achieving a revenue growth rate of 0.36% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 3.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Biogen's ROA excels beyond industry benchmarks, reaching 2.19%. This signifies efficient management of assets and strong financial health.
Debt Management: Biogen's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIIB

The Latest Analyst Ratings For Biogen

This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
The Board also declared a quarterly cash dividend of&nbsp;$0.45&nbsp;per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024.

Buybacks

AptarGroup Plans Repurchase Of Up To $500M Of Common Stock

W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for W.P. Carey, presenting an average target of $61.88, a high estimate of $66.00, and a low estimate of $56.00. Marking an increase of 2.93%, the current average surpasses the previous average price target of $60.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594053_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of W.P. Carey among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$56.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Conor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$66.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$63.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$60.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$63.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to W.P. Carey. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of W.P. Carey compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for W.P. Carey's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of W.P. Carey's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WPC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on W.P. Carey analyst ratings.</a>
<h2>Delving into W.P. Carey's Background</h2>
W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is primarily comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. most of the company's revenue comes from properties in the USA. The company's Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.
<h3>W.P. Carey's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: W.P. Carey's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -13.9%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: W.P. Carey's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 36.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): W.P. Carey's ROE stands out, surpassing industry averages. With an impressive ROE of 1.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.81%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.94, W.P. Carey adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 8 Analyst Ratings For W.P. Carey

Across the recent three months, 12 analysts have shared their insights on Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $240.0, a high estimate of $255.00, and a low estimate of $220.00. This current average has increased by 5.26% from the previous average price target of $228.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594037_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Reinsurance Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$244.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Andrew Kligerman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$235.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$222.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$242.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Wilma Burdis</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$250.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$255.00</td>
<td>-</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$236.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$239.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Mark Dwelle</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$252.00</td>
<td>$194.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reinsurance Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Reinsurance Gr compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Reinsurance Gr's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Reinsurance Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Reinsurance Gr analyst ratings.</a>
<h2>All You Need to Know About Reinsurance Gr</h2>
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
<h3>Reinsurance Gr's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Reinsurance Gr showcased positive performance, achieving a revenue growth rate of 17.4% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Reinsurance Gr's net margin is impressive, surpassing industry averages. With a net margin of 4.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Reinsurance Gr's ROE excels beyond industry benchmarks, reaching 2.11%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Reinsurance Gr's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.52, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Reinsurance Gr Stock: Analyst Perspectives (12 Ratings)

Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Birkenstock Holding, revealing an average target of $68.0, a high estimate of $77.00, and a low estimate of $60.00. Marking an increase of 3.03%, the current average surpasses the previous average price target of $66.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594020_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Birkenstock Holding by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janine Stichter</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Birkenstock Holding. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Birkenstock Holding compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Birkenstock Holding's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIRK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Birkenstock Holding analyst ratings.</a>
<h2>Get to Know Birkenstock Holding Better</h2>
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. The company operates in four operating segments based on its regional hubs: Americas, Europe and APMA (Asia Pacific, Middle East and Africa). The company sells its products through two main channels: business-to-business (B2B) and direct-to-consumer (DTC).
<h3>Birkenstock Holding's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Birkenstock Holding's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.35% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Birkenstock Holding's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.87%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Birkenstock Holding's ROA stands out, surpassing industry averages. With an impressive ROA of 1.51%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.57.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIRK

Evaluating Birkenstock Holding: Insights From 9 Financial Analysts

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Outlook Therapeutics (OTLK – Research Report), 60 ...

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Gritstone Oncology (GRTS)

Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Gritstone Oncology (GRTS – Research Report). The associated price target...

Buy Rating Affirmed on Gritstone Oncology Amidst Promising GRANITE Program Milestones and Upcoming PFS Data Release

Gritstone falls amid Phase 2 Granite data, corporate update

Gritstone Oncology (GRTS – Research Report) received a Hold rating and price target from JMP Securities analyst Roy Buchanan yesterday. The company...

Gritstone Oncology (GRTS) was downgraded to a Hold Rating at JMP Securities

H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Gritstone Oncology (GRTS – Research Report) today and set a price target of $0.50. ...

Neutral Rating and Price Target Revision for Gritstone Oncology Amidst Strategic and Clinical Uncertainties

In a report released today, Jonathan Miller from Evercore ISI maintained a Buy rating on Gritstone Oncology (GRTS – Research Report). The company's...

Gritstone Oncology (GRTS) Gets a Buy from Evercore ISI

Gritstone stock craters 50% in wake of Phase 2 data, corporate update

Gritstone downgraded by Jones, B. Riley over cancer vaccine data

Gritstone bio files for Chapter 11 bankruptcy protection, shares tumble

Gritstone Oncology ( ($GRTS) ) has shared an update. Gritstone bio, Inc., a biotech firm specializing in potent vaccines, has voluntarily filed for...

Gritstone Oncology Pursues Restructuring Through Chapter 11

GRTS

MRNA

OTLK

SXTP

Press Releases

Gritstone bio, Inc. Class Action: Levi & Korsinsky Reminds Gritstone Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 – GRTS

Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS

GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GRTS Investors Have Opportunity to Join Gritstone bio, Inc. Fraud Investigation with the Schall Law Firm

DEADLINE ALERT for GRTS, PATH, and NKE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Earnings

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Health Care

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

PATH

Aligos Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Biora Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Cyclo Therapeutics

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Geovax Labs

HCW Biologics

iBio

MiNK Therapeutics

Kairos Pharma

Longeveron

Lisata Therapeutics

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals

Orgenesis

Pieris Pharmaceuticals, Inc. - Common Stock

Pieris Pharmaceuticals

Pluri

RenovoRx

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Comments

Gritstone Bio

Intérêt court

Gritstone Bio (NASDAQ:GRTS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL